Добавил:
Sekretar
kiopkiopkiop18@yandex.ru
t.me/Prokururor I Вовсе не секретарь, но почту проверяю
Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз:
Предмет:
Файл:Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_1382_Библиотеки_им_академика_М_И_Перельмана.pdf
X
- •Contents
- •1. Thyroid Embryology, Anatomy, and Physiology: A Review for the Surgeon
- •2. The Assessment of Thyroid Nodules
- •3. Thyroid: Fine-Needle Aspiration Biopsy
- •4. Thyroid Imaging
- •5. Multinodular Goiter
- •6. Thyrotoxicosis and Thyroiditis: Causes, Investigation, and Management
- •7. Molecular Biology of Thyroid Cancer
- •8. Well-Differentiated Thyroid Cancer: An Overview and the Chernobyl Effect
- •9. Poorly Differentiated and Undifferentiated Thyroid Cancer
- •10. Postoperative Management of Well-Differentiated Thyroid Cancer
- •11. Medullary Thyroid Cancer
- •12. Technique of Thyroidectomy
- •13. Lymph Node Dissection in Thyroid Cancer
- •14. Management of the Laryngeal Nerves and Voice
- •15. Embryology, Anatomy, and Physiology of the Parathyroid Glands
- •16. Presentation and Diagnosis of Primary Hyperparathyroidism
- •17. Parathyroid Localization and Imaging
- •18. Intraoperative PTH Monitoring
- •19. Focused Parathyroidectomy
- •20. Parathyroid: Bilateral Neck Exploration
- •21. Reoperative Parathyroid Surgery
- •22. Management of Secondary and Tertiary Hyperparathyroidism
- •23. Parathyroid Carcinoma
- •24. Adrenal Embryology, Anatomy, and Physiology
- •25. Adrenal Imaging
- •26. Adrenal Venous Sampling
- •27. Primary Hyperaldosteronism
- •29. Pheochromocytoma and Paraganglioma
- •30. Adrenocortical Carcinoma
- •31. Incidentaloma
- •32. Adrenal Metastases and Rare Adrenal Tumors
- •33. Technique of Open and Laparoscopic Adrenalectomy
- •34. Laparoscopic Retroperitoneal Adrenalectomy
- •35. Pancreas: Embryology, Anatomy, and Physiology
- •36. Pancreatic Imaging: The Value for Surgery of Neuroendocrine Pancreatic Tumors

ENDOCRINE SURGERY
Table 16.5. Differential diagnosis of hypercalcemia
Category Condition Mechanism Indication for Diagnosis
Malignancy Solid tumor (PTHrP): lung, kidney, squamous cell
carcinomas of the head and neck/esophagus/
female genital tract
Osteoclastic metastasis: breast, prostate
Hematological: multiple myeloma, lymphoma,
leukemia
Hypercalcemic cytokines: interleukin 1 and 6, tumor
necrosis factor alpha, prostaglandins
Excess PTH Primary hyperparathyroidism
Sporadic or familial (MEN I and 2A)
Tertiary hyperparathyroidism
Increased
bone
turnover
Excess
vitamin D
(Calcitriol
induced)
Renal failure Secondary hyperparathyroidism
Iatrogenic Lithium
Familial Familial hypocalciuric hypercalcemia
Miscellaneous Addisonian crisis or glucocorticoid deficiency Lack of PTH
Hyperthyroidism
Immobilization
Paget’s disease
Acute intermittent porphyria
AIDS/HIV
Granulomatous disease (e.g., Sarcoidosis,
tuberculosis, histoplasmosis)
Milk alkali syndrome
Aluminium intoxication
Vitamin A intoxication (analogs used to treat acne)
Thiazide diuretics
Vitamin D intoxication
Tamoxifen
Theophylline
Salicylic acid intoxication
Idiopathic hypercalcemia of infancy
Osteolytic factors:
PTHrP
IL-1
IL-6
TNF
Prostaglandins
Calcitriol
Increased intestinal
and renal Ca
absorption
Osteolysis
Ca release from
skeleton
Increased 1,25-
dihydroxylated
vitamin D
Decrease in calciuria Impaired renal function
Increased PTH
Increased bone
turnover
Excess vitamin D
CaSR defect causing
decrease in
calciuria
?PTHrP
antagonist
Staging for malignancy
(CT, skeletal X-ray,
bone scan)
Elevated tumor markers
Elevated PTHrP and
calcitriol
Low PTH
Raised PTH and Ca
Low PTH
History
(X-rays, thyroid function,
HIV serology)
X-ray of lungs
Serology and
microbiology
Raised calcitriol
History
Medication history
Hypocalciuria
PTH normal or high
Ca/creatinine clearance
<0.01
Age and exclusion of
other causes
Low PTH
Raised PTHrP
Glucocorticoid tests
Low PTH
230
of bone assessed in the region of interest and
gives a value for BMD in that region. BMD
measurements correlate with load-bearing
capacity of the hip and spine and with the risk
of fracture [80]. The measurements are
expressed as a T-score and a Z-score which
represent the patient’s bone density in standard
deviations from their respective controls [81].
The T-score is a measurement of bone density compared with that of 30-year-old Caucasian adult of the same gender with peak bone
mass and is expressed in standard deviations

231
PRESENTATION AND DIAGNOSIS OF PRIMARY HYPERPARATHYROIDISM
from the control value of 0. A score within one
standard deviation (+1 to –1) is considered
normal, between –1 and –2.5 is classified as
osteopenia and a score below –2.5 is classified
as osteoporosis. The T-score is used to estimate
Fig. 16.3. DEXA scan of spine with severe osteoporosis.
the risk of developing a fracture. Established
osteoporosis is defined as a T-score below –2.5
and a history of at least one osteoporotic fracture (Figs. 16.3 and 16.4). The Z-score is a calculation of bone density compared with patients
Fig. 16.4. DEXA scan of right femur with osteoporosis.

232
ENDOCRINE SURGERY
of the same age group, size, and gender and is
therefore usually more relevant to clinical decision making in patients with pHPT.
Bone mineral density can be followed over
time as a response to treatment or for surveillance as well as being a research end point.
Newer tools aimed at measuring bone strength,
in particular quantitative ultrasound, are also
being studied. Indeed, quantitative ultrasound
of the heel appears to be almost as predictive of
hip fracture and all nonvertebral fractures as
DEXA at the femoral neck [81].
Conclusions
Primary hyperparathyroidism is not as uncommon as thought in the past. It is now diagnosed
more frequently and at an earlier stage in its
natural history. Whilst asymptomatic disease
may still be present, most patients present with a
subtle 21
st
century version of the disease that is,
however, far from innocuous. The diagnosis
requires a thorough understanding of calcium
metabolism and accurate biochemical investigations. Only once the diagnosis of pHPT has been
unequivocally made, can definitive treatment with
surgery be considered.
References
1. Organ, C. The history of parathyroid surgery,
1850–1996; the excelsior surgical society 1998 Edward
D Churchill lecture. J Am Coll Surg. 2000;191: 284–99.
2. Clark OH, Duh QY. Primary hyperparathyroidism. A
surgical perspective. Endocrinol & Metab Clin N Am.
1989;18(3):701–14, 284–99.
3. Adami S, Marocci C, Gatti D. Epidemiology of primary
hyperparathyroidism in Europe. J Bone Miner Res.
2002;17(suppl. 2):N18–23.
4. Melton JL. The epidemiology of primary hyperparathyroidism in North America. J Bone Miner Res. 2002;17(suppl.
2):N12–7.
5. Anonymous. Proceedings of the NIH Consensus Development Conference on diagnosis and management of
asymptomatic primary hyperparathyroidism. Bethesda,
Maryland, October 29–31, 1990. J Bone Miner Res.
1991;6(suppl 2):S1–166.
6. Heath H, Hodgson SF, Kennedy MA. Primary hyperparathyroidism: incidence, morbidity and economic
impact in a community. N Eng J Med. 1980;302:189.
7. Lundgren E, Rastad J, Thrufjell E, A˚kerstr¨om G,
Ljunghall S. Population-based screening for primary
hyperparathyroidism withserumcalciumandparathyroid hormone values in menopausal women. Surgery. 1997;121(3):287–94.
8. Lundgren E, Hagstrom EG, Lundin J, Winnerback K,
Roos J, Ljunghall S, Rastad J. Primary hyperparathyroidism revisited in menopausal women with serum
calcium in the upper normal range at populationbased screening 8 years ago. World J Surg. 2002;
26(8):931–6.
9. Stephen AE, Chen KT, Milas M, Siperstein AE. The
coming of age of radiation-induced hyperparathyroidism: evolving patterns of thyroid and parathyroid disease after head and neck irradiation. Surgery.
2004;136(6):1143–53.
10. Hundley JC, Woodrum DT, Saunders BD, Doherty GM,
Gauger PG. Revisiting lithium-associated hyperparathyroidism in the era of intraoperative parathyroid
hormone monitoring. Surgery. 2005;138(6):1027–31.
11. Cetani F, Pardi E, Ambrogini E, Lemmi M, Borsari S,
Cianferotti L, Vignali E, Viacava P, Berti P, Mariotti S,
Pinchera A, Marcocci C. Genetic analyses in familial
isolated hyperparathyroidism: implication for clinical
assessment and surgical management. Clin Endocrinol.
2006;64(2):146–52.
12. Benson L, Ljunghall S, A˚kerstr¨om G,¨Oberg K. Hyperparathyroidism presenting as the first lesion in multiple
endocrine neoplasia type 1 (MEN1). Am J Med.
1987;82:731–737.
13. Malone JP, Srivastava A, Khardori R. Hyperparathyroidism and multiple endocrine neoplasia. Otolaryngol
Clin N Am. 2004;37(4):715–36.
14. Nilsson IL, Yin L, Lundgren E, Rastad J, Ekbom A.
Clinical presentation of primary hyperparathyroidism
in Europe – nationwide cohort analysis on mortality
from nonmalignant causes. J Bone Min Res
2002;17(Suppl 2):N68–74.
15. Ljunghall S, Per Hellman P, Rastad J, A˚kerstr¨om G.
Primary hyperparathyroidism: epidemiology, diagnosis
and clinical picture. World J Surg. 1991;15(6):681–7.
16. Jacob JJ, John M, Thomas N, Chacko A, Cherian R,
Selvan B, Nair A, Seshadri M. Does hyperparathyroidism cause pancreatitis? A South Indian experience and a
review of published work. ANZ JSurg. 2006;76(8):740–4.
17. Carella MJ, Gossain VV. Hyperparathyroidism and
pregnancy: case report and review. J Gen Int Med.
1992;7(4):448–53.
18. Clark OH, Wilkes W, Siperstein AE, Duh QY. Diagnosis
and management of asymptomatic hyperparathyroidism: safety, efficacy, and deficiencies in our knowledge.
J Bone Min Res. 1991;6(Suppl 2):S135–42.
19. Ware JE Jr, Sherbourne CD. The MOS 36-item shortform health survey (SF-36). I. Conceptual framework
and item selection. Med Care. 1992;30(6):473–83.
20. Burney RE, Jones KR,Peterson M, Christy B, Thompson
NW. Surgical correction of primary hyperparathyroidism improves quality of life. Surgery. 1998;124:987–92.
21. Caillard C, Sebag F, Mathonnet M, Gibelin H, Brunaud L,
Loudot C,Kraimps JL,Hamy A, BreslerL, Charbonnel B,
Leborgne J, Henry JF, Nguyen JM, Mirallie E. Prospective evaluation of quality of life (SF-36v2) and nonspecific symptoms before and after cure of primary
hyperparathyroidism (1-year follow-up). Surgery.
2007;141(2):153–9.
22. Pasieka JL, Parsons LL. Prospective surgical outcome
study of relief of symptoms following surgery in patients
with primary hyperparathyroidism. World J Surg.
1998;22(6):513–8.

233
PRESENTATION AND DIAGNOSIS OF PRIMARY HYPERPARATHYROIDISM
23. Sadler GP, Mihai R, Jeevan D. Pasieka’s parathyroid
symptoms scores correlate with SF-36 scores in patients
undergoing parathyroidectomy for primary hyperparathyroidism. International surgical week 2007 Abstract
073.
24. Pasieka JL, Parsons LL, Demeure MJ, Wilson S, Malycha
P, Jones J, et al. A patient-based surgical outcome tool
demonstrating improvement of symptoms following
parathyroidectomy in patients with primary hyperparathyroidism. World J Surg. 2002;26:942–9.
25. Sywak MS,Knowlton ST,Pasieka JL, ParsonsLL, JonesJ.
Do the National Institutes of Health consensus guidelines for parathyroidectomy predict symptom severity
and surgical outcome in patients with primary hyperparathyroidism? Surgery. 2002;132(6):1013–9.
26. Grey A, Evans M, Stapleton J, Reid I.Body weight andbone
mineral density in postmenopausal women with primary
hyperparathyroidism. Ann Int Med. 1994;121(10):745–9.
27. Nilsson IL, Yin L, Lundgren E, Rastad J, Ekbom A.
Clinical presentation of primary hyperparathyroidism
in Europe – nationwide cohort analysis on mortality
from nonmalignant causes. J Bone Min Res. 2002;17
(Suppl 2):N68–74.
28. Lundgren E, LindL, PalmerM, JakobssonS, Ljunghall S,
Rastad J. Increased cardiovascular mortality and normalized serum calcium in patients with mild hypercalcemia followed up for 25 years. Surgery. 2001;130(6):
978–85.
29. Hagstrom E, Lundgren E, Mallmin H, Rastad J, Hellman
P. Positive effect of parathyroidectomy on bone mineral
density in mild asymptomatic primary hyperparathyroidism. J Int Med. 2006;259(2):191–8.
30. Hagstrom E, Lundgren E, Lithell H, Berglund L, Ljunghall S, Hellman P, Rastad J. Normalized dyslipidaemia
after parathyroidectomy in mild primary hyperparathyroidism: population-based study over five years.
Clin Endocrinol. 2002;56(2):253–60.
31. Valdemarsson S, Lindblom P, Bergenfelz A. Metabolic
abnormalities related to cardiovascular risk in primary
hyperparathyroidism: effects of surgical treatment. J Int
Med. 1998;244(3):241–9.
32. Bollerslev J, Jansson S, Mollerup CL, Nordenstrom J,
Lundgren E, Torring O, Varhaug JE, Baranowski M,
Aanderud S, Franco C, Freyschuss B, Isaksen GA,
Ueland T, Rosen T. Medical observation, compared
with parathyroidectomy, for asymptomatic primary
hyperparathyroidism: a prospective, randomized trial.
J Clin Endocrinol Metab. 2007;92(5):1687–92.
33. Silverberg SJ, ShaneE, Jacobs TP, Siris ES, Gartenberg F,
Seldin D, ClemensTL, BilezikianJP. Nephrolithiasisand
bone involvement in primary hyperparathyroidism. Am
J Med. 1990;89(3):327–34.
34. Dauphine RT, Riggs BL, Scholz DA. Back pain and
vertebral crush fractures: an unemphasized mode of
presentation for primary hyperparathyroidism. Ann
Int Med. 1975;83(3):365–7.
35. Melton LJ 3rd, Atkinson EJ, O’Fallon WM, Heath H 3rd.
Risk of age-related fractures in patients with primary
hyperparathyroidism. Arch Int Med. 1992;152(11):
2269–73.
36. Dempster DW, Muller R, Zhou H, Kohler T, Shane E,
Parisien M, Silverberg SJ,Bilezikian JP. Preserved threedimensional cancellous bone structure in mild primary
hyperparathyroidism. Bone 2007;41(1):19–24.
37. Parisien M, Cosman F, Mellish RW, Schnitzer M, Nieves
J, Silverberg SJ, Shane E, Kimmel D, Recker RR, Bilezikian JP et al. Bone structure in postmenopausal hyperparathyroid, osteoporotic, and normal women. J Bone
Min Res. 1995;10(9):1393–9.
38. VanderWalde LH, Liu IL, O’Connell TX, Haigh PI. The
effect of parathyroidectomy on bone fracture risk in
patients with primary hyperparathyroidism. Arch
Surg. 2006;141(9):885–9.
39. Gardner EC Jr, Hersh T. Primary hyperparathyroidism
and the gastrointestinal tract. Southern Med J.
1981;74(2):197–9.
40. Mowat E, Gunn A, Paterson CR. Hyperparathyroidism
in peptic ulcer patients. BJS. 1981;68(7):455–8
41. Gardner EC Jr, Hersh T. Primary hyperparathyroidism
and the gastrointestinal tract. Southern Med J. 1981;
74(2):197–9.
42. Bess M, Edis A, Von Heerden J. Hyperparathyroidism
and pancreatitis. Chance or a causal association? JAMA.
1980;243:246–7.
43. Shepherd J. Hyperparathyroidism presenting as pancreatitis or complicated by postoperative pancreatitis.
Aust NZ J Surg. 1996;66:85–7.
44. Carnaille B, Oudar C, Pattou F, Combemale F, Rocha J,
Proye C. Pancreatitis and primary hyperparathyroidism: forty cases. Aust NZ J Surg. 1998;68:117–9.
45. Caroll M, Schade D. A practical approach to hypercalcaemia. Am Fam Physician. 2003;67(9):1959–66.
46. Kebebew E, Clark O. Parathyroid adenoma, hyperplasia,
and carcinoma. Surg Oncol Clin North Am. 1998;7:
721–48.
47. Binstock ML, Mundy GR. Effect of calcitonin and glucocorticoids in combination on the hypercalcaemia of
malignancy. Ann Intern Med. 1980;87:269–72.
48. Lew J, Solorzano C, Irvin G. Long term results of parathyroidectomy for hypercalcaemic crisis. Arch Surg.
2006;141:696–9.
49. Ziegler R. Hypercalcaemic crisis. J Am Soc Nephrol.
2001;12:S3–9.
50. Inabnet W, Lee J, Henry JF, Sebag F. Parathyroid disease. In: Lennard T, ed., A companion to specialist
surgical practice: endocrine surgery, 3rd ed. Amsterdam: Elsevier Saunders, 2006;6–8.
51. Major PP, ColemanRE. Zoledronic acid inthe treatment
of hypercalcaemia of malignancy: results of the international clinical development program. Semin Oncol
2001;28(2 suppl 7):17–24.
52. Silva OL, Becker KL. Salmon calcitonin in the treatment of hypercalcaemia. Arch Int Med. 1973;132:
337–9.
53. Binstock ML, Mundy GR. Effect of calcitonin and glucocorticoids in combination on the hypercalcaemia of
malignancy. Ann Int Med. 1980;93:269–72.
54. Rodriguez A, Trujillo MJ, Herrero T, et al. Allergy to
calcitonin. Allergy. 2001;58:801.
55. Davidson TG. Conventional management of hypercalcaemia of malignancy. Am J Health-System Pharm.
2001;58(suppl 3):S8–15.
56. Lukert BP, Raisz LG. Glucocorticoid-induced osteoporosis: pathogenesis and management. Ann Intern
Med. 1990;112:352–64.
57. Strumpf M, Kowalski MA, Mundy GR. Effects of glucocorticoids on osteoclas-activating factor. J Lab Clin
Med. 1978;92:772–8.

234
ENDOCRINE SURGERY
58. Tisell L, Hedback G, Jansson S, Lindtstedt G, Zachrisson
B. Management of hyperparathyroid patients with grave
hypercalcaemia. World J of Surg. 1991;15:730–7.
59. Lew J, Solorzano C, Irvin G. Long term results of parathyroidectomy for hypercalcaemic crisis. Arch Surg.
2006;141:696–9.
60. Monchik J, Gorgun E. Normocalcaemic hyperparathyroidism in patients with osteoporosis. Surgery. 2004;136:
1242–6.
61. Mather HG. Hyperparathyroidism with normal serum
calcium. BMJ. 1953;2:424–5.
62. Maruani G, Hurtig A, Paillard M, Houillier P. Normocalcaemic primary hyperparathyroidism: evidence for a
generalized target-tissue resistance to parathyroid hormone. J Clin Endocrinol Metab. 2003;88:4641–8.
63. Lowe H, McMahonJ, Rubin M, Bilezikian J, Silvergerg S.
Normocalcaemic primary hyperparathyroidism: further
characterization of a new clinical phenotype. J Clin
Endocrinol Metab. 2007;92:3001–5.
64. Hagstrom E, Lundgren E, Rastad J, Hellman P. Metabolic abnormalities in patients with normocalcaemic
hyperparathyroidism detected at a population-based
screening. Eur J Endocrinol. 2006;155:33–9.
65. Poole Jr GV, Albertson AD, Myers RT. Normocalcaemic
hyperparathyroidism revisited. Am Surg. 1983;49:668–71.
66. Hagag P, Revet-Zak I, Hod N et al. Diagnosis of normocalcaemic hyperparathyroidism by oral calcium loading
test. J Endocrinol Invest. 2003;26(4):327–32.
67. Monchick JM. Normocalcaemic hyperparathyroidism.
Surgery. 1995;118(6):917–23.
68. Payne, M. Albumin-adjusted calcium. Med Lab Obs
2004; 36(5).
69. Brown EM. Four-parameter model of the sigmoidal
relationship between parathyroid hormone release and
extracellular calcium concentration in normal and
abnormal parathyroid tissue. J Clin Endocrinol Metab.
1986;56:572–81.
70. BrownEM,PollakM,SeidmanCE,etal.Calcium-ionsensing cell-surface receptors. N Engl J Med. 1995;
333:234–40.
71. Khosla S, Ebelling PR, Firek AF, et al. Calcium infusion
suggests a ‘set point’ abnormality of parathyroid gland
function in familial benign hypercalcaeima and more
complex disturbances in primary hyperparathyroidism.
J Clin Endocrinol Metab. 1993;76:715–20.
72. KIfor S, Moore FD Jr, Wang P, et al. Reduced immunostaining for the extracellular Ca
primary and uremic secondary hyperparathyroidism. J
Clin Endocrinol Metab. 1996;81:1598–606.
73. Ariyan C, Sosa J. Assessment and management of
patients with abnormal calcium. Crit Care Med.
2004;32 suppl:S146–54.
74. Strewler GJ, Budayr AA, Clark OH, Nissenson RA. Production of parathyroid hormone by a malignant nonparathyroid tumor in a hypercalcemic patient. J Clin
Endocrinol Metab. 1993;76(5):1373–5.
75. Attie MF, Gill Jr JR, Stock JL, Spiegel AM, Downs Jr RW,
Levine MA, Marx SJ. Urinary calciumexcretion infamilial hypocalciuric hypercalcemia. Persistence of relative
hypocalciuria after induction of hypoparathyroidism. J
Clin Invest. 1983 August; 72(2): 667–76.
76. Vieweg J, Teh C, Freed K, Leder RA, Smith RH, Nelson
RH, et al. Unenhanced helical computerized tomography for theevaluation ofpatients withacute flankpain. J
Urol. 1998;160(3 Pt 1):679–84.
77. Sinclair D, Wilson S, ToiA, GreenspanL. Theevaluation
of suspected renal colic: ultrasound scan versus excretory urography. Ann Emerg Med. 1989;18(5):556–9.
78. Erwin BC, Carroll BA, Sommer FG. Renal colic: the
role of ultrasound in initial evaluation. Radiology.
1984;152(1):147–50.
79. World Health Organization. Assessment of fracture risk
and its application to screening for postmenopausal osteoporosis. Technical report series 843. Geneva: WHO, 1994.
80. KanisJA,DelmasP,BurckhardtP,CooperC,TorgersonD,
on behalf of the European Foundation for Osteoporosis
and Bone Disease. Guidelines for diagnosis and management of osteoporosis. Osteoporosis Int 1997;7:390–406.
81. Osteoporosis Prevention, Diagnosis, and Therapy. NIH
Consensus Statement 2000; 17(1): 1–36.
+2
-sensing receptor in

17
Parathyroid Localization and Imaging
Jean-Franc¸ois Henry, David Taı¨eb and Sam Van Slycke
Introduction
For many years bilateral cervical exploration
with identification of four glands remained the
gold standard in parathyroid surgery, and routine preoperative imaging for initial surgery was
considered unnecessary and not cost effective.
In 1986, John L. Doppman stated ‘‘Inmy opinion,
the only localizing study indicated in a patient
with untreated primary hyperparathyroidism
(HPT) is to localize an experienced parathyroid
surgeon’’ [1]. Times have changed, and undoubtedly it is the progress of imaging studies that has
modified the surgical management of patients
with HPT and helped the development of new
surgical techniques.
Many imaging modalities have been reported. In
the past, when only invasive localization procedures
[angiography and selective venous sampling (SVS)]
were available, localization of abnormal parathyroid
glands was limited to reoperative cases. Today, the
development and the reported efficacy of noninvasive techniques have tempted many endocrinologists and many surgeons to order some ofthese new
noninvasive techniques on patients undergoing
first-time parathyroidectomy.
Moreover, more than half the surgeons
performing parathyroid surgery now consider
that bilateral parathyroid exploration is no
longer the only option in all patients with
HPT. Patients presenting with solitary adenoma
can be candidates for new focused surgical
procedures. This emphasizes the current role
of preoperative localization studies in the surgical management of patient with primary HPT.
After an overview of the various noninvasive
tests and invasive tests currently used we will
discuss the indications for each of them.
Preoperative Localization
Tests
Noninvasive Tests
Ultrasonography
High-resolution ultrasonography (US) with a
probe of 7.5 or 10 MHz is used in first-line parathyroid imaging for many reasons.It iseasily and
quickly performed, and well tolerated by the
patient. It does not require administration of
contrast medium and does not emit radiation.
It provides good anatomic information about
masses in the neck and, when performed by
expert radiologists, 95% of adenomas that
weigh in excess of 1,000 mg can be identified.
In addition it is the least expensive preoperative
localization technique. However US can only
assess the cervical region.
The sensitivity of US is operator and material
dependent. The patient should be examined in
the supine position with the neck in hyperextension. A pillow can be placed under the shoulders
if the patient has a short neck. A high-frequency
J.G.H. Hubbard et al. (eds.), Endocrine Surgery, Springer Specialist Surgery Series,
DOI 10.1007/978-1-84628-881-4_17, Ó Springer-Verlag London Limited 2009
235

linear transducer (7.5–10 MHz) is used to obtain
optimal depth penetration of 3–4 cm. A bilateral
and comparative scan should be performed in
transverse section, then in longitudinal section.
In transverse section, the examination concentrates on an area defined by the longus colli
muscles posteriorly, the thyroid gland anteriorly, the trachea medially, and the carotid
artery laterally. The scan is then performed in
cranial and caudal directions. An additional
scan can be performed with the head of the
patient turned away to the side, and during
deglutition to optimize the latero-esophageal
images. The anterosuperior mediastinum is
examined by inclining the transducer deeply in
a retrosternal direction.
Enlarged parathyroid glands appear as a
homogeneous well-demarcated mass, which is
hypoechoic in contrast to the hyperechoic
thyroid tissue. They are usually solid, but large
adenomas may have a cystic component.
The examiner should note the precise location with respect to surrounding structures,
particularly the thyroid gland, and the depth
from the skin. Enlarged superior parathyroid
glands are usually found adjacent to the posterior aspect of the thyroid lobe (Fig. 17.1). They
tend to migrate posteriorly and in a downward
direction (Fig. 17.2), sometimes into the postero-superior mediastinum. Enlarged inferior
236
ENDOCRINE SURGERY
Fig. 17.2. Ultrasonography. Arrow 1: right thy roid lobe. Arrow 2:
superior or inferior parathyroid adenoma posterior to the inferior
pole of the thyroid lobe.
parathyroid glands are usually found immediately adjacent to the inferior pole of the thyroid
lobes (Fig. 17.3). In 25% of cases, they are found
at a variable distance from the lower pole of a
thyroid lobe (Fig. 17.4). These adenomas, lying
in the thyrothymic ligament or in the upper
cervical portion of the thymus, remain located
Fig. 17.1. Ultrasonography. Arrow 1: right thyroid lobe. Arrow 2:
right superior parathyroid adenoma posterior to the two superior
thirds of the thyroid lobe.
Fig. 17.3. Ultrasonography. Arrow 1: right thyroid lobe. Arrow 2:
right inferior parathyroid adenoma located just below the tip of
the inferior pole of thyroid lobe and in the superficial plane.

237
PARATHYROID LOCALIZATION AND IMAGING
Fig. 17.4. Ultrasonography. Arrow 1: inferior pole of right
thyroid lobe. Arrow 2: right inferior parathyroid adenoma
along thyrothymic ligament.
or the acoustic shadow of bone when located
behind the clavicle or sternum. Sensitivity falls
to 40% for reoperative localization since such
patients have an increased incidence of ectopic
mediastinal parathyroid adenomas or multiglandular disease (MGD) [8].
Intrathyroid parathyroid adenomas are
well imaged by US but they have an ultrasonographic appearance indistinguishable from that
of hypoechoic thyroid nodules. As for other
nonparathyroid anatomical structures, the
diagnosis can be confirmed by US-directed
fine needle aspiration (FNA) for parathyroid
hormone (PTH) which is highly sensitive and
specific [9–11]. False-positive results vary from
15 to 20% [12, 13].
Many factors may explain the variable
reported accuracy of US, but it is likely that
preoperative US localization is highly dependent on the skill and experience of the examiner.
US is particularly useful when used in conjunction with other modalities such as FNA and
parathyroid scintigraphy.
superficially in the neck or in the superior mediastinum. Some inferior adenomas located at
the posterolateral part of the inferior pole of
the thyroid lobe tend to migrate posteriorly
(Fig. 17.2) and in a downward direction, and
are found in a paratracheal or a paraesophageal
position. US provides good anatomic detail that
permits the surgeon to know the exact location
of the adenoma in the neck and make a judicious choice of surgical access.
Finally, a color-flow Doppler or a power-flow
Doppler is performed to test the vascularization
of the area and define the artery branches
involved.
In patients without prior parathyroid surgery, US has been shown to have sensitivity
and a specificity of 70–85% and 90–95%, respectively [2–5]. The sensitivity is highly dependent
on the size of the parathyroid gland. The limit of
detection is approximately 5 mm. Fewer than
50% of adenomas weighing less than 200 mg are
identified by US. This can explain the reduced
accuracy of US in the presence of parathyroid
hyperplasia, in which enlargement of individual
glands may be minimal [6, 7]. Other common
causes of false-negative examinations include
associated multinodular goiter, adenomas located
in the tracheoesophageal groove which can be
obscured by the acoustic shadow of the trachea,
Parathyroid Scintigraphy
Over recent decades, several protocols of
parathyroid scintigraphy have been evaluated
[14–16].
imaging since the introduction of
because of the poorer quality images and unfavorable dosimetry.
use of
isonitrile), a lipophilic compound, is radiolabeled
with
philized kits. Following injection, the radiopharmaceutical is rapidly and passively accumulated
within the mitochondria of metabolically active
cells, including thyroid and parathyroid cells.
Tracer retention is dependent on several factors
such as mitochondria content, cell cycle, and
expression of P-glycoprotein efflux protein. Two
protocols for sestamibi scanning are in current
use: the single isotope-dual phase protocol and
the subtraction protocol.
cept of single radiopharmaceutical/dual phase
imaging [18]. This approach is based on the
differential sestamibi retention between parathyroid and thyroid tissue. After injection of
99m
201
Tl has been abandoned in parathyroid
Coakley and coworkers first reported on the
99m
Tc-sestamibi for parathyroid
99m
Tc-sestamibi
imaging [17]. Sestamibi (methoxy-isobutyl-
99m
Tc-pertechnetate, using commercial lyo-
Taillefer and coworkers introduced the con-
Tc-sestamibi, tracer retention is prolonged

238
ENDOCRINE SURGERY
in parathyroid hyperfunctioning lesions whereas
it washes out more rapidly from normal thyroid
tissue. This retention is presumably related to
oxyphil cells in parathyroid lesions which are
rich in mitochondria. The dual protocol requires
early (15 min postinjection) and delayed images
(at 1 and 2–3 h, depending on thyroid washout).
Image acquisition is centered over the 140 Kev
photopeak. On the early images, activity of the
parathyroid lesion may be more intense, intense
as, or less intense than thyroid activity. The
detectability of disease is dependent on parathyroid–thyroid activity ratio and location of the
tumour. On the delayed images, parathyroid
lesions are easily identified (Fig. 17.5). However,
washout of parathyroid lesions compared to
thyroid may vary between subjects.
This technique is easy and simple, but has
some specific limits such as parathyroid adenomas that clear sestamibi, low mitochondrial
content (hyperplastic glands), and abnormal
tracer retention in thyroid nodules (hyperfunctioning nodules, cancer). In cases of multinodular thyroid disease, additional further delayed
images are sometimes needed to overcome
these pitfalls.
When a subtraction protocol is used,
99m
Tc-sestamibi is used in conjunction with
another radionuclide specific to the thyroid.
99m
Tc-pertechnetate and
used radioisotopes for thyroid scintigraphy.
99m
Tc-pertechnetate is obtained from
generators, has a half-life of 6 h and emits a
140-Kev gamma ray.
123
I are the most widely
99Mo/99m
123
I is cyclotron produced,
Tc
has a half-life of 13 h, and a gamma ray emission
of 159 Kev. Both tracers are concentrated in
thyrocytes via NIS protein but only
nified in thyroid follicles.
The main advantage of using
123
Iisorga-
123
I is that
thyroid and parathyroid images can be acquired
simultaneously in a dual energy window set up.
The disadvantage is the increased cost of the
protocol related to
2–4 h before acquisition. With
123I.123
I is usually injected
99m
Tc-pertechnetate, the thyroid image can be acquired either
before or after the completion of sestamibi acquisition. When
99m
Tc-pertechnetate is injected
after sestamibi acquisition, both the dual phase
protocol and the subtraction protocol can be
performed. After normalization, thyroid images
are digitally subtracted from sestamibi images.
The residual image corresponds to an image of
Fig. 17.5. Dual phase protocol: injection of 740 of
static images at 15, 60, 120, and 180 min. The images shows more delayed washout of
(white arrow) than from the normal thyroid, resulting in increase contrast. A parallel hole collimator was used.
99m
Tc-sestamibi at T0. Dynamic planar images (from 1 to 10 min postinjection),
99m
Tc-sestamibi from the parathyroid lesion

239
PARATHYROID LOCALIZATION AND IMAGING
Ior
123
I at T–2h, injection of 740 of
prolapsed behind the lower pole of the thyroid
gland. These adenomas can be located very
deeply in the neck, in paraesophageal or retroesophageal locations, that may be missed by
inexperienced surgeons (Figs. 17.7 and 17.8). By
contrast, inferior glands are mostly located at the
tip of the inferior pole of the thyroid lobe or along
99m
the thyrothymic tract on planar images and
remain anterior on SPECT imaging (Fig. 17.9).
Tc-
SPECT also enables a better localization of large
adenomas prolapsed in the mediastinum and
ectopic glands (Figs. 17.10 and 17.11). There is
no consensus regarding the timing of SPECT
acquisition. Our preference is to perform SPECT
45–60 min after
there is sufficient residual activity in thyroid for
determining the relative position of parathyroid
adenomas. Finally, the use of SPECT–CT fusion
images is particularly helpful for localizing ectopic
glands (Fig. 17.12).
There is no consensus regarding which
imaging protocol should be used. The subtraction method seems to have a higher sensitivity
than dual phase imaging [20–24]. However,
only a few studies have compared both proce-
Fig. 17.6. Subtraction protocol: injection of 12 MBq of
pinhole acquisition at T + 3 (20 min acquisition). A typical example of parathyroid adenoma. (A)
image. (B) The
lesion in the right lower pole of the thyroid. Simple visual comparison of two images is unable to reveal differences in tracer
distribution. The detection of the adenoma needs digital subtraction of images (after normalization of thyroid image).
123
I scan shows a normal thyroid gland. (C) The subtraction image (
the parathyroid. Simple visual comparison of
two images can also reveal differences in tracer
distribution, but the detection of small lesions
needs the computer manipulation of images
(Fig. 17.6). When using two separate acquisitions
for both isotopes, patient movement between
data acquisitions may lead to false-positive
images. Another potential pitfall of the subtraction protocol is reduced or absent
123
pertechnetate thyroid uptake, which renders the
subtraction image invalid.
Parathyroid scintigraphy should include
views of the neck and the mediastinum (from
the angle of the mandible to the heart) because
ectopic glands are widely distributed along the
parathyroid cell migration routes.
The type of collimator used can affect the
sensitivity of the procedure. The parallel hole
collimator enables simultaneous imaging of
both neck and mediastinum. The pinhole collimator provides higher resolution images and
magnifies the structure being imaged. However,
the field of view is smaller than for the parallel
hole collimator, and images of the neck and
mediastinum should be obtained separately.
99m
Tc-sestamibi-
99m
99m
Tc-sestamibi at T0, dual tracer planar
99m
Tc-sestamibi pinhole planar
123
I) demonstrates a parathyroid
Tc-sestamibi injection because
duresinanintrapatientanalysis.Thereported
Single-Photon Emission Tomography
Single-photon emission tomography (SPECT)
or anterior oblique views can be helpful for
more precise localization of adenomas. SPECT
provides simultaneous 3D information on
both the neck and the mediastinum. There is a
further improvement in sensitivity and image
quality when iterative reconstruction is used
instead of filtered back-projection [19]. SPECT
is particularly useful for reclassifying apparently
inferior adenomas to superior adenomas
sensitivity of parathyroid scintigraphy ranges
from 70 to 100%, and mainly depends upon
gland weight and PTH values, but is not related
to calcium levels. SPECT may provide
improvement in sensitivity in comparison to
planar imaging [25–29]. In our experience,
sensitivity reaches 90% when PTH >150 ng/
ml or gland weight >1,000 mg, with only marginal improvement in sensitivity with SPECT
[30]. In smaller lesions, sensitivity may vary
between tumors.
Соседние файлы в папке Библиотека им академика М.И. Перельмана
